摘要
目的探讨纽约食管鳞状上皮癌抗原-1(NY-ESO-1)和黑色素瘤抗原基因-A3(MAGE-A3)在进展期胃印戒细胞癌组织中的表达和临床意义。方法收集2004年4月至2014年7月进展期胃印戒细胞癌组织81例,采用免疫组织化学法检测肿瘤组织中NY-ESO-1和MAGE-A3的蛋白表达水平。统计分析两者表达与临床病理特征和预后的关系。结果81例胃印戒细胞癌组织中NY-ESO-1的阳性表达率为9.9%(8/81),MAGE-A3的阳性表达率为28.4%(23/81)。NY-ESO-1和MAGE-A3的表达呈正相关(r=0.25,P=0.024)。NY-ESO-1表达与TNM分期和神经侵犯有关(P<0.05),与年龄、性别、病理类型、Lauren分型、肿瘤位置和脉管侵犯无关(P>0.05)。MAGE-A3表达与年龄有关(P=0.020),而与性别、TNM分期、病理类型、Lauren分型、肿瘤位置、神经侵犯和脉管侵犯无关(P>0.05)。NY-ESO-1阳性表达患者的中位总生存时间(OS)为13.0个月(95%CI:0~40.7个月),阴性表达者为20.5个月(95%CI:16.6~24.4个月),差异无统计学意义(P=0.605)。MAGE-A3阳性表达患者的中位OS为20.5个月(95%CI:8.0~33.0个月),阴性表达者为20.0个月(95%CI:15.1~24.9个月),差异无统计学意义(P=0.922)。结论NY-ESO-1和MAGE-A3在进展期胃印戒细胞癌组织中均有一定程度的表达,两者作为靶点的免疫治疗在胃印戒细胞癌中的潜在价值值得进一步探索。
Objective To explore the expression and clinical significance of New York esophageal squamous cell carcinoma antigen-1(NY-ESO-1)and melanoma antigen gene-A3(MAGE-A3)protein levels in advanced gastric signet ring cell carcinoma.Methods From Apr 2004 to Jul 2014,gastric signet ring cell carcinoma samples from 81 patients were stained by immunohistochemistry to evaluate the expression level of NY-ESO-1 and MAGE-A3.The correlation of their expression with clinicopathological characteristics and prognosis was analyzed.Results Positive NY-ESO-1 samples was found in 9.9%(8/81)of 81 gastric signet ring cell carcinoma samples,while positive MAGE-A3 was found in 28.4%(23/81)of all samples.There was a positive correlation between NY-ESO-1 and MAGE-A3 levels(r=0.25,P=0.024).NY-ESO-1 expression was related to TNM stages and nerve invansion(P<0.05),but not related to age,gender,pathological types,Lauren types,tumor location or vascular invasion(P>0.05).The expression of MAGEA3 was related to age(P=0.020),but had no correlation with gender,TNM stage,pathological types,Lauren types,tumor location,nerve invasion and vascular invasion(P>0.05).There was no significant difference between NY-ESO-1 positive patients'median overall survival(OS)and negative patients'(13.0 months,95%CI:0-40.7months vs.20.5 months,95%CI:16.6-24.4 months,P=0.605).Also,there was no significant difference between MAGE-A3 positive patients'median OS and negative patients'(20.5 months,95%CI:8.0-33.0 months vs.20.0 months,95%CI:15.1-24.9 months,P=0.922).Conclusion In advanced gastric signet ring cell carcinoma tissues,NY-ESO-1 and MAGE-A3 expressed in some degree.The potential value of immunotherapy targeted on them in gastric signet ring cell carcinoma deserved being further studied.
作者
聂春兰
汪越
金沈樱
吴鸿雁
樊祥山
禹立霞
刘宝瑞
魏嘉
NIE Chunlan;WANG Yue;JIN Shenying;WU Hongyan;FAN Xiangshan;YU Lixia;LIU Baorui;WEI Jia(Department of Oncology,Nanjing Lishui People's Hospital,Nanjing 211200,China)
出处
《临床肿瘤学杂志》
CAS
北大核心
2019年第10期898-902,共5页
Chinese Clinical Oncology
基金
“重大新药创制”国家科技重大专项(2019ZX09301150)
国家自然科学基金资助项目(81572329)
